ClinicalTrials.gg
CompletedNCT05085548Updated Apr 27, 2026

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

A Phase 1 interventional study of ProAgio Dose Levels (DL) 1,2,3 and ProAgio Dose Levels (DL) 4,5,6 in Advanced Pancreatic Cancer and Solid Tumor Malignancies, sponsored by ProDa BioTech, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by ProDa BioTech, LLC · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
658th of 1,573
46 · median 37
Started
2021
with 87 others
Phase 1
555 of 1,850
74 open now
Registered
1,459th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 658th largest by enrollment of the 1,573 interventional ones that give a count, is one of 88 that started in 2021, is one of 555 in phase 1, and was the 1,459th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.

Read the detailed description

Pancreatic cancer is the third leading cause of death from cancer in the United States. The median overall survival for patients with metastatic disease who are receiving the most effective combination of chemotherapy regimens remains less than 1 year.

ProAgio has been evaluated in nonclinical pharmacology, safety pharmacology, pharmacokinetic (PK), and toxicity studies. It has demonstrated efficacy at treating pancreatic cancer and prolonging survival in mice.

ProAgio is being developed for intravenous (IV) administration. All participants will receive ProAgio until disease progression, unacceptable toxicity, or withdrawal from study. Subjects in the dose escalation cohorts who will be administered ProAgio at doses ranging from 3.2 to 36.8 mg/kg.

Following the dose escalation phase, an expansion cohort of patients with advanced nonendocrine pancreatic adenocarcinoma will be administered ProAgio at the maximum tolerated dose (MTD) from the dose escalation phase. Patients will also be offered optional co-administration of gemcitabine (Gem). The expansion cohort will contain two arms: A) Biopsy Arm (8 participants), and B) Standard Arm (8 participants). Tumor biopsies performed pre- and post- (on Cycle 2 Day 2-3) ProAgio treatment are optional for participants enrolled in the Standard Arm, but mandatory for participants enrolled in the Biopsy Arm.

03

Conditions studied

  • Advanced Pancreatic Cancer
  • Solid Tumor Malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the Escalation Cohort:

  • Histologic or cytologic diagnosis of a solid tumor for which no curative therapy exists.
  • Individuals must have evaluable disease, either by clinical exam, biochemical markers (including but not limited to CA 19-9 serum tumor marker for pancreatobiliary cancer, or other appropriate tumor marker in other tumor types), and/or radiographic studies.
  • Individuals must have received at least one prior systemic treatment for advanced disease.
  • For the Expansion Cohort:
  • Histologic or cytologic diagnosis of non-neuroendocrine pancreatic cancer. Individuals with mixed acinar-neuroendocrine histology are eligible.
  • All Participants must have , per 1.1.
  • All individuals must have advanced or recurrent disease and have received at least one prior systemic treatment. Specifically:

    • Individuals with , locally advanced/unresectable, or borderline resectable pancreatic cancer at diagnosis, must have received at least one prior systemic treatment and still be considered ineligible for potentially curative resection.
    • Individuals who have undergone surgical resection and have tumor recurrence that is not amenable to local therapy, are eligible if:
  • Tumor recurs within six months of the completion of therapy, OR
  • Further standard of care therapy is not a viable option due to prior resistance or intolerance, or a medical to both FOLFIRINOX (or NALIRIFOX) and gemcitabine-based chemotherapy
  • Individuals in the Arm of the expansion cohort must have disease amenable to safe biopsy and willingness to undergo the procedure.
  • All individuals must be more than 14 days removed from most recent standard of care or experimental drug treatment for their tumor.
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of ProAgio in individuals \<18 years of age, children are excluded from this study.
  • performance status ≤ 2 ( ≥>60%).
  • Individuals must have adequate organ and marrow function as defined below:
  • Aabsolute (ANC) ≥1,000/mcL
  • hemoglobinHemoglobin (hgb) ≥9 g/ dL
  • plateletsPlatelets ≥75,000/mcL
  • (AST)/ alanine transaminase (ALT) ( ≤ 2.5 x institutional (ULN). AST and ALT (up to 5x ULN) is permitted for participants individuals with liver metastases)
  • Total ≤1.5 X institutional ULN
  • Creatinine within normal institutional limits OR
  • ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
  • Serum albumin >2.5 mg/dL without intravenous supplementation
  • Individuals must also have:
  • Baseline interval of ≤ 470 ms
  • Baseline resting heart rate > 45 beats per minute and \<100 beats per minute
  • Individuals of (IOCBP) and individuals able to father a child men must agree to use an effective method of as follows:
  • IOCBP must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after the last dose of study drug(s).
  • Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 6 months after the last dose of the study drug(s). We also will recommend individuals able to father a child with IOCBP partners to ask them to be on an effective birth control (hormonal, intrauterine device [(IUD)], surgical sterilization.
  • Ability of individual to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary malignant CNS tumor.
  • Individuals who are receiving any other agents.
  • Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including but not limited to significant pulmonary disease other than that related to the primary cancer, uncontrolled diabetes mellitus, unstable angina, significant cardiovascular disease (such as Class III or IV cardiac disease) and/or psychiatric illness/social situations within 12 weeks that would limit compliance with study requirements.
  • Individuals with known diagnosis of a chronic neurologic disorders (such as multiple sclerosis, Huntington's disease, Parkinson's disease, or uncontrolled epilepsy) which causes motor disturbance, visual disturbance or seizure and could confound assessment of neurologic toxicity caused by the study drug.
  • Pregnant or nursing individuals are excluded from this study because ProAgio is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ProAgio, breastfeeding should be discontinued if the mother is treated with ProAgio.
  • Individuals with or with that are untreated, have required treatment within the last 4 weeks, or anti-convulsant therapy in the last 14 days. For dose escalation cohort only: Individuals with any known CNS metastases are excluded. Those with symptoms suggestive of possible CNS metastases (such as new headaches) must undergo brain MRI as part of screening.
  • Individuals who have undergone a recent minor surgical procedure (within \<14 days) such as biliary stenting or major surgical procedure (within ≥ 28 days).
  • Individuals who have undergone recent (within ≤ 14 days) external beam radiation therapy are excluded. Individuals who have undergone recent (within ≤ 28 days) treatment with radioactive therapeutics (such as Y90 or radio-immune conjugates) are ineligible.
  • Individuals with uncontrolled bleeding episodes \<28 days prior to enrollment are excluded.
  • Individuals with active or uncontrolled infections are excluded.
  • Individuals with and detectable viral load are excluded. Patents on appropriate highly active anti-retroviral therapy with undetectable viral load are eligible.
  • Individuals with a history of or C are excluded unless there is documented evidence of effective treatment and/or cure with undetectable viral load.
  • Individuals with recent (within \< 28 days) thromboembolic disease including but not limited to acute coronary syndrome, stroke, or , recent deep vein thrombosis or pulmonary embolism.
  • Individuals with thromboembolic disease including but not limited to acute coronary syndrome, stroke, or transient ischemic attack, recent deep vein thrombosis or pulmonary embolism who have continued symptoms, or who are not on stable doses of appropriate antiplatelet / anticoagulant regimens are excluded.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Participants will receive ProAgio in escalating doses.

    Drug: ProAgio Dose Levels (DL) 1,2,3 · Drug: ProAgio Dose Levels (DL) 4,5,6 · Drug: ProAgio Dose Levels 4a,5a,6a

  • Experimental
    Expansion Biopsy Arm

    Pre- and post-treatment tumor biopsy is optional for participants enrolled in the standard arm, but mandatory for participants enrolled in the biopsy arm.

    Drug: ProAgio Dose Levels 4a,5a,6a

  • Experimental
    Standard Arm

    Participants will receive ProAgio at the RP2D and may elect to receive concurrent gemcitabine beginning with the start of Cycle 2.

    Drug: ProAgio Dose Levels (DL) 4,5,6 · Drug: ProAgio Dose Levels 4a,5a,6a

Interventions

06

What researchers measure

Primary outcomes

  1. Determine Recommended Phase 2 Dose (RP2D)

    Following completion of the dose escalation cohort, all available data relating to the pharmacokinetics, pharmacodynamics, efficacy and safety of ProAgio will be reviewed by the study team including the Principle Investigator, clinical pharmacology collaborators and the sponsor. A single ideal dose will then be selected for further investigation in the dose escalation cohort. This ideal dose may or may not be the same as the MTD.

    Time frame: 3 Years

Secondary outcomes

  1. Safety and Tolerability of ProAgio

    Toxicities will be tabulated and reported per dose level according to grade and type of toxicity experienced. This will take place during the dose escalation phase as well as during the expansion phase.

    Time frame: 3 Years

  2. Evaluate the Maximum Plasma Concentration of ProAgio

    ProAgio concentrations will be measured by a validated ELISA assay modified from the assay used in non-clinical studies. This PK data will be used to mathematically describe the kinetic disposition of ProAgio in humans following the current dosing schedule.

    Time frame: 3 Years

  3. Evaluate the area under the curve of ProAgio

    Statistical analysis of study data will calculate the area under the plasma concentration curve for each study subject that received ProAgio.

    Time frame: 3 Years

  4. Evaluate the Serum half-life of ProAgio

    ProAgio Serum half-life will be determined using standard statistical calculations. .

    Time frame: 3 Years

  5. Evaluate the volume of distribution of ProAgio

    If there are sufficient participant data available, a population PK analyses will be conducted to identify covariates that may be significantly associated with the inter-individual variability for a particular PK parameter (e.g. clearance of volume of distribution).The NCI CPP may also conduct dose-response and/or exposure-response analyses that will assess PK/PD relationships with relevant biomarkers, clinical response, and adverse event data.

    Time frame: 3 Years

  6. Rate of study drug elimination in research participants

    58 study participants will have study drug concentration levels analyzed with regard to drug elimination. Results will be expressed in units of inverse time, i.e. 1/hr or 1/day.

    Time frame: 3 Years

  7. Objective Response Rate (ORR)

    Make a preliminary assessment of anti-tumor activity by measuring objective response rate (ORR),

    Time frame: 3 Years

  8. Disease control rate (DCR).

    Make a preliminary assessment of anti-tumor activity by measuring disease control rate at 18 weeks (DCR).

    Time frame: At 18 Weeks

  9. Assess serum tumor marker CA19-9 or appropriate tumor specific marker.

    Make a preliminary assessment of anti-tumor activity by measuring change in relevant serum tumor marker CA19-9 appropriate tumor specific marker.

    Time frame: Day 1 of each treatment cycle and 30 days after the last dose of study therapy.

Other outcomes

  1. Assess whether a host antibody response against ProAgio develops with repeated administration

    Change in ADA titer, as measured between baseline and EOT

    Time frame: 2 Years

  2. Assess biologic effect of ProAgio on apoptosis of tumor cells in tumor tissue

    Pre- to on-therapy tumor biopsy specimen assessment of changes in apoptosis of tumor cells

    Time frame: 2 Years

  3. Assess biologic effect of ProAgio on integrin αvβ3 expression in tumor tissue

    Pre- to on-therapy tumor biopsy specimen assessment of changes in integrin αvβ3 expression (% of cells expressing both integrins)

    Time frame: 2 Years

  4. Assess biologic effect of ProAgio on tumor collagen density and architecture

    Pre- to on-therapy tumor biopsy specimen assessment of changes in tumor collagen density and architecture (Sirius Red stain)

    Time frame: 2 Years

  5. Assess biologic effect of ProAgio on tumor vasculature

    Pre- to on-therapy tumor biopsy specimen assessment of changes in tumor vasculature (% of CD31 positive cells)

    Time frame: 2 Years

  6. Assess biologic effect of ProAgio on CAF and CASCs populations

    Pre- to on-therapy tumor biopsy specimen assessment of changes on CAF and CASCs populations (% of α-SMA positive cells)

    Time frame: 2 Years

  7. Assess biologic effect of ProAgio on changes on Localization / populations of tumor cells

    Pre- to on-therapy tumor biopsy specimen assessment of changes on Localization / populations of tumor cells as measured by Digital spatial profiling (DSP)

    Time frame: 2 Years

  8. Identify surrogate circulating biomarkers of ProAgio bioactivity in serum PKM2 concentrations

    Pre- to on-therapy change in serum PKM2 concentration

    Time frame: 2 Years

  9. Identify surrogate circulating biomarkers of ProAgio bioactivity in CECs quantities

    Pre- to on-therapy change in CECs quantities

    Time frame: 2 Years

  10. Identify surrogate circulating biomarkers of ProAgio bioactivity on circulating fibroblasts quantities

    Pre- to on-therapy change on circulating fibroblasts quantities

    Time frame: 2 Years

  11. Identify surrogate circulating biomarkers of ProAgio bioactivity in Circulating αvβ3 expressing cells

    Pre- to on-therapy change in Circulating αvβ3 expressing cells (all cells and CTCs)

    Time frame: 2 Years

  12. Assess the safety of co-administering ProAgio with gemcitabine (Gem)

    For cycles where participants receive both ProAgio and Gem, tabulated list of: * Grade ≥ 3 and higher adverse events (AEs) * All AEs attributable to research * Whether or not stopping rules for optional addition of Gem are met

    Time frame: 2 Years

  13. Evaluate maximum plasma concentration (Cmax) of ProAgio when given in combination with Gem

    For cycles where participants receive both ProAgio and Gem determine maximum plasma concentration (Cmax)

    Time frame: 2 Years

  14. Evaluate serum half-life of ProAgio when given in combination with Gem

    For cycles where participants receive both ProAgio and Gem estimate serum half-life

    Time frame: 2 Years

07

Study locations

1 site
  • National Cancer Institute
    Bethesda, Maryland 20892, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Apr 2025, 41 months.

Of 171 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's 41 months is close to that.

Counting every sponsor, half of 380 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2021
First posted
Oct 20, 2021
StartActual
Oct 29, 2021
Primary completionActual
Apr 24, 2025
CompletionActual
Apr 10, 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05085548
Lead sponsor
ProDa BioTech, LLC
Responsible party
Sponsor
First posted
Oct 20, 2021
Start date
Oct 29, 2021
Primary completion
Apr 24, 2025
Completion
Apr 10, 2026
Last update
Apr 27, 2026

Study contacts

Anish Thomas, MBBS, MD
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Integrin Alpha V Beta 3-targeting Protein ACT50

Start the discussion